ID   NAGS_HUMAN              Reviewed;         534 AA.
AC   Q8N159; B2RAZ9; Q8IWR4;
DT   13-SEP-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2002, sequence version 1.
DT   10-MAY-2017, entry version 129.
DE   RecName: Full=N-acetylglutamate synthase, mitochondrial;
DE            EC=2.3.1.1;
DE   AltName: Full=Amino-acid acetyltransferase;
DE   Contains:
DE     RecName: Full=N-acetylglutamate synthase long form;
DE   Contains:
DE     RecName: Full=N-acetylglutamate synthase short form;
DE   Contains:
DE     RecName: Full=N-acetylglutamate synthase conserved domain form;
DE   Flags: Precursor;
GN   Name=NAGS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], TISSUE SPECIFICITY, AND
RP   VARIANTS NAGSD PRO-279; PRO-430 AND ARG-484.
RX   PubMed=12754705; DOI=10.1002/humu.10216;
RA   Haeberle J., Schmidt E., Pauli S., Kreuder J.G., Plecko B., Galler A.,
RA   Wermuth B., Harms E., Koch H.G.;
RT   "Mutation analysis in patients with N-acetylglutamate synthase
RT   deficiency.";
RL   Hum. Mutat. 21:593-597(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Small intestine;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 94-534, ENZYME REGULATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=12459178; DOI=10.1016/S0006-291X(02)02696-7;
RA   Caldovic L., Morizono H., Gracia Panglao M., Gallegos R., Yu X.,
RA   Shi D., Malamy M.H., Allewell N.M., Tuchman M.;
RT   "Cloning and expression of the human N-acetylglutamate synthase
RT   gene.";
RL   Biochem. Biophys. Res. Commun. 299:581-586(2002).
RN   [4]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 377-534 IN COMPLEX WITH
RP   N-ACETYL-GLUTAMATE, ENZYME REGULATION, SUBSTRATE-BINDING SITES,
RP   SUBUNIT, AND MUTAGENESIS OF TYR-441; ASN-479 AND TYR-485.
RX   PubMed=23894642; DOI=10.1371/journal.pone.0070369;
RA   Zhao G., Jin Z., Allewell N.M., Tuchman M., Shi D.;
RT   "Crystal structure of the N-acetyltransferase domain of human N-
RT   acetyl-L-glutamate synthase in complex with N-acetyl-L-glutamate
RT   provides insights into its catalytic and regulatory mechanisms.";
RL   PLoS ONE 8:E70369-E70369(2013).
RN   [5]
RP   VARIANTS NAGSD ARG-200; PRO-410; PRO-430; ARG-484 AND THR-518, AND
RP   CHARACTERIZATION OF VARIANTS NAGSD ARG-200; PRO-410; PRO-430; ARG-484
RP   AND THR-518.
RX   PubMed=15878741; DOI=10.1016/j.bbadis.2005.02.006;
RA   Schmidt E., Nuoffer J.-M., Haeberle J., Pauli S., Guffon N.,
RA   Vianey-Saban C., Wermuth B., Koch H.G.;
RT   "Identification of novel mutations of the human N-acetylglutamate
RT   synthase gene and their functional investigation by expression
RT   studies.";
RL   Biochim. Biophys. Acta 1740:54-59(2005).
RN   [6]
RP   VARIANTS NAGSD VAL-167; LEU-260; MET-264; ASN-291; ARG-391; CYS-398;
RP   ASP-457 AND CYS-512.
RX   PubMed=27037498; DOI=10.1002/humu.22995;
RA   Sancho-Vaello E., Marco-Marin C., Gougeard N., Fernandez-Murga L.,
RA   Ruefenacht V., Mustedanagic M., Rubio V., Haeberle J.;
RT   "Understanding N-acetyl-L-glutamate synthase deficiency: mutational
RT   spectrum, impact of clinical mutations on enzyme functionality, and
RT   structural considerations.";
RL   Hum. Mutat. 37:679-694(2016).
CC   -!- FUNCTION: Plays a role in the regulation of ureagenesis by
CC       producing the essential cofactor N-acetylglutamate (NAG), thus
CC       modulating carbamoylphosphate synthase I (CPSI) activity.
CC   -!- CATALYTIC ACTIVITY: Acetyl-CoA + L-glutamate = CoA + N-acetyl-L-
CC       glutamate.
CC   -!- ENZYME REGULATION: Increased by L-arginine.
CC       {ECO:0000269|PubMed:12459178, ECO:0000269|PubMed:23894642}.
CC   -!- PATHWAY: Amino-acid biosynthesis; L-arginine biosynthesis; N(2)-
CC       acetyl-L-ornithine from L-glutamate: step 1/4.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:23894642}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix.
CC   -!- TISSUE SPECIFICITY: Highly expressed in the adult liver, kidney
CC       and small intestine. Weakly expressed in the fetal liver, lung,
CC       pancreas, placenta, heart and brain tissue.
CC       {ECO:0000269|PubMed:12459178, ECO:0000269|PubMed:12754705}.
CC   -!- DOMAIN: The Amino-acid kinase domain (AAK) mediates binding of the
CC       allosteric activator L-arginine.
CC   -!- PTM: Probably processed by mitochondrial processing peptidase
CC       (MPP). The long form has not yet been isolated (By similarity).
CC       {ECO:0000250}.
CC   -!- DISEASE: N-acetylglutamate synthase deficiency (NAGSD)
CC       [MIM:237310]: Rare autosomal recessively inherited metabolic
CC       disorder leading to severe neonatal or late-onset hyperammonemia
CC       without increased excretion of orotic acid. Clinical symptoms are
CC       somnolence, tachypnea, feeding difficulties, a severe neurologic
CC       presentation characterized by uncontrollable movements,
CC       developmental delay, visual impairment, failure to thrive and
CC       hyperammonemia precipitated by the introduction of high-protein
CC       diet or febrile illness. {ECO:0000269|PubMed:12754705,
CC       ECO:0000269|PubMed:15878741, ECO:0000269|PubMed:27037498}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the acetyltransferase family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=N-acetylglutamate synthase
CC       entry;
CC       URL="https://en.wikipedia.org/wiki/N-acetylglutamate_synthase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY116537; AAM75385.1; -; Genomic_DNA.
DR   EMBL; AY116538; AAM75386.1; -; mRNA.
DR   EMBL; AK314432; BAG37046.1; -; mRNA.
DR   EMBL; AY158070; AAN76451.1; -; mRNA.
DR   CCDS; CCDS11473.1; -.
DR   RefSeq; NP_694551.1; NM_153006.2.
DR   UniGene; Hs.8876; -.
DR   PDB; 4K30; X-ray; 2.10 A; A/B/X/Y=377-534.
DR   PDBsum; 4K30; -.
DR   ProteinModelPortal; Q8N159; -.
DR   SMR; Q8N159; -.
DR   BioGrid; 127816; 1.
DR   IntAct; Q8N159; 1.
DR   MINT; MINT-1431825; -.
DR   STRING; 9606.ENSP00000293404; -.
DR   DrugBank; DB00142; L-Glutamic Acid.
DR   iPTMnet; Q8N159; -.
DR   PhosphoSitePlus; Q8N159; -.
DR   BioMuta; NAGS; -.
DR   DMDM; 74714699; -.
DR   EPD; Q8N159; -.
DR   PaxDb; Q8N159; -.
DR   PeptideAtlas; Q8N159; -.
DR   PRIDE; Q8N159; -.
DR   Ensembl; ENST00000293404; ENSP00000293404; ENSG00000161653.
DR   GeneID; 162417; -.
DR   KEGG; hsa:162417; -.
DR   UCSC; uc002ies.4; human.
DR   CTD; 162417; -.
DR   DisGeNET; 162417; -.
DR   GeneCards; NAGS; -.
DR   HGNC; HGNC:17996; NAGS.
DR   HPA; HPA027300; -.
DR   MalaCards; NAGS; -.
DR   MIM; 237310; phenotype.
DR   MIM; 608300; gene.
DR   neXtProt; NX_Q8N159; -.
DR   OpenTargets; ENSG00000161653; -.
DR   Orphanet; 927; Hyperammonemia due to N-acetylglutamate synthetase deficiency.
DR   PharmGKB; PA134968729; -.
DR   eggNOG; KOG2436; Eukaryota.
DR   eggNOG; COG0548; LUCA.
DR   GeneTree; ENSGT00390000005602; -.
DR   HOGENOM; HOG000007983; -.
DR   HOVERGEN; HBG080036; -.
DR   InParanoid; Q8N159; -.
DR   KO; K11067; -.
DR   OMA; LTMEPVL; -.
DR   OrthoDB; EOG091G0FPD; -.
DR   PhylomeDB; Q8N159; -.
DR   TreeFam; TF332628; -.
DR   BRENDA; 2.3.1.1; 2681.
DR   Reactome; R-HSA-70635; Urea cycle.
DR   UniPathway; UPA00068; UER00106.
DR   ChiTaRS; NAGS; human.
DR   GenomeRNAi; 162417; -.
DR   PRO; PR:Q8N159; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000161653; -.
DR   CleanEx; HS_NAGS; -.
DR   ExpressionAtlas; Q8N159; baseline and differential.
DR   Genevisible; Q8N159; HS.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0004042; F:acetyl-CoA:L-glutamate N-acetyltransferase activity; EXP:Reactome.
DR   GO; GO:0034618; F:arginine binding; IBA:GO_Central.
DR   GO; GO:0006526; P:arginine biosynthetic process; IBA:GO_Central.
DR   GO; GO:0006536; P:glutamate metabolic process; TAS:BHF-UCL.
DR   GO; GO:0000050; P:urea cycle; TAS:Reactome.
DR   InterPro; IPR016181; Acyl_CoA_acyltransferase.
DR   InterPro; IPR001048; Asp/Glu/Uridylate_kinase.
DR   InterPro; IPR011243; GlcNAc_Synth_met.
DR   InterPro; IPR006855; Vertebrate-like_GNAT_dom.
DR   Pfam; PF04768; NAT; 1.
DR   PIRSF; PIRSF036442; NAGS_animal; 1.
DR   SUPFAM; SSF53633; SSF53633; 1.
DR   SUPFAM; SSF55729; SSF55729; 1.
DR   PROSITE; PS51731; GNAT_NAGS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acyltransferase; Complete proteome; Disease mutation;
KW   Mitochondrion; Reference proteome; Transferase; Transit peptide;
KW   Urea cycle.
FT   TRANSIT       1     18       Mitochondrion. {ECO:0000255}.
FT   CHAIN        19    534       N-acetylglutamate synthase long form.
FT                                {ECO:0000255}.
FT                                /FTId=PRO_0000041930.
FT   CHAIN        51    534       N-acetylglutamate synthase short form.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000041931.
FT   CHAIN        92    534       N-acetylglutamate synthase conserved
FT                                domain form. {ECO:0000250}.
FT                                /FTId=PRO_0000041932.
FT   DOMAIN      375    526       N-acetyltransferase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00532}.
FT   REGION       19    376       Amino-acid kinase domain (AAK).
FT   REGION      474    479       Substrate binding.
FT   BINDING     401    401       Substrate.
FT   BINDING     444    444       Substrate.
FT   VARIANT     167    167       M -> V (in NAGSD; unknown pathological
FT                                significance; dbSNP:rs760267963).
FT                                {ECO:0000269|PubMed:27037498}.
FT                                /FTId=VAR_077329.
FT   VARIANT     200    200       C -> R (in NAGSD; markedly decreases
FT                                activity). {ECO:0000269|PubMed:15878741}.
FT                                /FTId=VAR_023505.
FT   VARIANT     260    260       P -> L (in NAGSD; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:27037498}.
FT                                /FTId=VAR_077330.
FT   VARIANT     264    264       T -> M (in NAGSD; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:27037498}.
FT                                /FTId=VAR_077331.
FT   VARIANT     279    279       A -> P (in NAGSD).
FT                                {ECO:0000269|PubMed:12754705}.
FT                                /FTId=VAR_023506.
FT   VARIANT     291    291       I -> N (in NAGSD; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:27037498}.
FT                                /FTId=VAR_077332.
FT   VARIANT     391    391       L -> R (in NAGSD; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:27037498}.
FT                                /FTId=VAR_077333.
FT   VARIANT     398    398       S -> C (in NAGSD; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:27037498}.
FT                                /FTId=VAR_077334.
FT   VARIANT     410    410       S -> P (in NAGSD; markedly decreases
FT                                activity). {ECO:0000269|PubMed:15878741}.
FT                                /FTId=VAR_023507.
FT   VARIANT     430    430       L -> P (in NAGSD; markedly decreases
FT                                activity; dbSNP:rs104894605).
FT                                {ECO:0000269|PubMed:12754705,
FT                                ECO:0000269|PubMed:15878741}.
FT                                /FTId=VAR_023508.
FT   VARIANT     457    457       G -> D (in NAGSD; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:27037498}.
FT                                /FTId=VAR_077335.
FT   VARIANT     484    484       W -> R (in NAGSD; markedly decreases
FT                                activity; dbSNP:rs104894606).
FT                                {ECO:0000269|PubMed:12754705,
FT                                ECO:0000269|PubMed:15878741}.
FT                                /FTId=VAR_023509.
FT   VARIANT     512    512       Y -> C (in NAGSD; unknown pathological
FT                                significance; dbSNP:rs752415489).
FT                                {ECO:0000269|PubMed:27037498}.
FT                                /FTId=VAR_077336.
FT   VARIANT     518    518       A -> T (in NAGSD; markedly decreases
FT                                activity; dbSNP:rs745511282).
FT                                {ECO:0000269|PubMed:15878741}.
FT                                /FTId=VAR_023510.
FT   MUTAGEN     441    441       Y->F: 15% reduction in catalytic
FT                                activity. {ECO:0000269|PubMed:23894642}.
FT   MUTAGEN     479    479       N->A: 7-fold reduction in catalytic
FT                                activity. {ECO:0000269|PubMed:23894642}.
FT   MUTAGEN     485    485       Y->F: 10-fold reduction in catalytic
FT                                activity. {ECO:0000269|PubMed:23894642}.
FT   CONFLICT     94     94       E -> M (in Ref. 3; AAN76451).
FT                                {ECO:0000305}.
FT   STRAND      378    382       {ECO:0000244|PDB:4K30}.
FT   HELIX       383    385       {ECO:0000244|PDB:4K30}.
FT   HELIX       388    399       {ECO:0000244|PDB:4K30}.
FT   HELIX       407    411       {ECO:0000244|PDB:4K30}.
FT   HELIX       412    414       {ECO:0000244|PDB:4K30}.
FT   STRAND      415    420       {ECO:0000244|PDB:4K30}.
FT   STRAND      424    435       {ECO:0000244|PDB:4K30}.
FT   STRAND      438    447       {ECO:0000244|PDB:4K30}.
FT   HELIX       451    467       {ECO:0000244|PDB:4K30}.
FT   STRAND      471    476       {ECO:0000244|PDB:4K30}.
FT   HELIX       482    487       {ECO:0000244|PDB:4K30}.
FT   STRAND      489    494       {ECO:0000244|PDB:4K30}.
FT   STRAND      496    503       {ECO:0000244|PDB:4K30}.
FT   HELIX       508    510       {ECO:0000244|PDB:4K30}.
FT   HELIX       511    519       {ECO:0000244|PDB:4K30}.
SQ   SEQUENCE   534 AA;  58156 MW;  1328039080EB936C CRC64;
     MATALMAVVL RAAAVAPRLR GRGGTGGARR LSCGARRRAA RGTSPGRRLS TAWSQPQPPP
     EEYAGADDVS QSPVAEEPSW VPSPRPPVPH ESPEPPSGRS LVQRDIQAFL NQCGASPGEA
     RHWLTQFQTC HHSADKPFAV IEVDEEVLKC QQGVSSLAFA LAFLQRMDMK PLVVLGLPAP
     TAPSGCLSFW EAKAQLAKSC KVLVDALRHN AAAAVPFFGG GSVLRAAEPA PHASYGGIVS
     VETDLLQWCL ESGSIPILCP IGETAARRSV LLDSLEVTAS LAKALRPTKI IFLNNTGGLR
     DSSHKVLSNV NLPADLDLVC NAEWVSTKER QQMRLIVDVL SRLPHHSSAV ITAASTLLTE
     LFSNKGSGTL FKNAERMLRV RSLDKLDQGR LVDLVNASFG KKLRDDYLAS LRPRLHSIYV
     SEGYNAAAIL TMEPVLGGTP YLDKFVVSSS RQGQGSGQML WECLRRDLQT LFWRSRVTNP
     INPWYFKHSD GSFSNKQWIF FWFGLADIRD SYELVNHAKG LPDSFHKPAS DPGS
//
